2018
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis
2017
Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).
Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.Peer-Reviewed Original ResearchHepatocellular carcinomaCause mortalityVeterans Administration Corporate Data WarehouseStage of HCCBCLC stage BBCLC stage DLiver disease severityAdvanced-stage cancerUseful prognostic markerAssociation of changesDate of deathLogistic regression analysisPotential hepatocellular carcinomaManual chart abstractionRegression analysisCorporate Data WarehouseChart abstractionBCLC 0Tumor burdenLiver diseaseTumor stagingUS veteransPrognostic markerHCC casesDiagnostic confirmation